摘要
目的评价血清VEGF在恶性肿瘤患者治疗中的临床价值。方法对337例未经治疗的恶性肿瘤患者、25例术后及22例术后复发的恶性肿瘤患者应用ELISA法进行了血清VEGF含量及阳性率检测,并以47例良性肿瘤及61例健康成人作为对照组。结果恶性肿瘤患者血清VEGF含量及阳性率明显高于健康对照组及良性肿瘤组(P<0.001),宫颈癌患者术后7￣10d较术前明显增高(P<0.02),术后1￣2个月恶性肿瘤患者较术前明显下降(P<0.001),而术后复发者又显著上升(P>0.05)。结论监测恶性肿瘤患者血清VEGF的动态变化有助于了解患者病情的发展。
Objective To evaluate the clinical applied value of serum vascular endothelial growth factor (VEGF) in therapeutic process of patients with malignant tumor. Methods Serum VEGF levels and positive rates were measured by ELISA in 337 untreated cancer patients, 25 postoperative and 22 recurring postoperative patients with malignant tumor, while 47 benign tumor and 61 healthy individuals as controls. Results Serum VEGF levels and positive rates were significantly higher in patients with various malignant tumors than in benign tumors and healthy controls (P <0.001). During 7 ~ 10 postoperative day, patients with cervical cancer had a higher VEGF than those before operation(P <0.02), until 1~2 months after operation, the postoperative elevated VEGF returned to lower level than preoperative in patients with malignant tumor(P<0.001). While recurrence happened, the level increased significantly(P>0.05). Conclusions It was helpful to get a message of pathogenetic condition of malignant tumor patients whose serum VEGF was dynamically monitored.
出处
《肿瘤研究与临床》
CAS
2005年第3期180-182,共3页
Cancer Research and Clinic
